Q1 2024 EPS Estimates for Edwards Lifesciences Co. (NYSE:EW) Lowered by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs reduced their Q1 2024 EPS estimates for Edwards Lifesciences in a research report issued to clients and investors on Wednesday, April 17th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will earn $0.65 per share for the quarter, down from their previous forecast of $0.66. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q2 2024 earnings at $0.71 EPS, FY2024 earnings at $2.75 EPS, FY2025 earnings at $3.11 EPS, FY2026 earnings at $3.52 EPS, FY2027 earnings at $3.94 EPS and FY2028 earnings at $4.28 EPS.

EW has been the topic of a number of other reports. Evercore ISI raised their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Stifel Nicolaus raised their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. Finally, Mizuho raised their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Edwards Lifesciences Trading Down 0.6 %

Edwards Lifesciences stock opened at $85.94 on Friday. The firm’s 50-day moving average is $90.15 and its 200-day moving average is $78.37. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a market cap of $51.73 billion, a P/E ratio of 37.37, a PEG ratio of 4.29 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 earnings per share.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock valued at $17,166,254. Company insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Moneta Group Investment Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the period. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $658,390,000. Brown Advisory Inc. boosted its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its holdings in shares of Edwards Lifesciences by 440.0% during the third quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after purchasing an additional 2,860,000 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of Edwards Lifesciences by 197.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after purchasing an additional 2,286,119 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.